Lexeo Therapeutics, a New York City-based genetic medicine company, focuses on therapies for hereditary and acquired diseases and recently went public on November 3, 2023. Its pipeline includes cardiovascular candidates LX2006 and LX2020, both undergoing clinical evaluation.
Lexeo Therapeutics (LXEO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Lexeo Therapeutics's actual EPS was -$0.89, missing the estimate of -$0.69 per share, resulting in a -28.59% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
